Literature DB >> 2454647

The influence of aprotinin on regional absorption of soluble human insulin.

D R Owens1, J P Vora, J Birtwell, S Luzio, T M Hayes.   

Abstract

1. The absorption of 6U of soluble human insulin following subcutaneous injection into the anterior abdominal wall, thigh and into the thigh following admixture with aprotinin was assessed in normal subjects. The plasma immunoreactive insulin profiles were determined during a 6 h post injection period in subjects receiving concomitantly somatostatin to suppress endogenous insulin secretion. 2. Subcutaneous injection of human insulin into the anterior abdominal wall compared with the thigh led to significantly higher incremental insulin levels between 30 and 50 min (P less than 0.05) followed by lower values at 240-300 min (P less than 0.05). The absorption of soluble human insulin from a subcutaneous depot is faster from the anterior abdominal wall compared with the thigh associated with a faster clearance from plasma. 3. Injection into the thigh of insulin admixed with aprotinin resulted in higher plasma insulin levels at 10 min (P less than 0.001) and 20 min (P less than 0.05) compared with insulin given alone. Similarly, the insulin level was significantly higher with the admixture between 10 and 20 min (P less than 0.05) compared with insulin into the anterior abdominal wall. 4. Admixture of insulin with aprotinin therefore leads to an acceleration of the early phase of absorption from subcutaneous tissue due to a local hyperaemic effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454647      PMCID: PMC1387807          DOI: 10.1111/j.1365-2125.1988.tb03329.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Adipose tissue blood flow and insulin disappearance from subcutaneous tissue.

Authors:  K Kølendorf; J Bojsen; S L Nielsen
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

2.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

3.  Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1972-08       Impact factor: 10.122

4.  The effect of aprotinin on the absorption of subcutaneously injected regular insulin in normal subjects.

Authors:  M Berger; H J Cüppers; P A Halban; R E Offord
Journal:  Diabetes       Date:  1980-01       Impact factor: 9.461

5.  Influence of aprotinin on insulin absorption and subcutaneous blood flow in type 1 (insulin-dependent) diabetes.

Authors:  B Linde; R Gunnarsson
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

6.  Aprotinin induced lipohypertrophy and glomerulonephritis in an insulin dependent diabetic.

Authors:  P Dandona; A Mier; F Boag; M Chappell; A G Beckett
Journal:  Diabetes Res       Date:  1985-07

7.  Absorption kinetics and biologic effects of subcutaneously injected insulin preparations.

Authors:  M Berger; H J Cüppers; H Hegner; V Jörgens; P Berchtold
Journal:  Diabetes Care       Date:  1982 Mar-Apr       Impact factor: 19.112

8.  Prostaglandin E1 accelerates subcutaneous insulin absorption in insulin-dependent diabetic patients.

Authors:  G Williams; J C Pickup; A C Collins; H Keen
Journal:  Diabet Med       Date:  1984-07       Impact factor: 4.359

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.